06622 ZHAOKE OPHTH-B
- 1.420
- -0.040-2.74%
ZHAOKE OPHTH-B News
Good performance, cold stock price, why is Médecins Opticiens "good but not popular" (06622)?
Behind the abnormal stock price performance, is it due to the inadequate market potential of the company's new drugs, the underperformance of the fundamentals, or is there another hidden mystery?
Department of Health: The "1+" approval mechanism will be expanded to all new drugs starting from November, embodying the concept of "Hong Kong, a Good Drug Harbor".
The Department of Health announced today (25th) that, in accordance with the measures announced in the Chief Executive's Policy Address for 2024, the "1+" approval mechanism will be expanded to all new drugs starting from November 1 this year, including vaccines and advanced therapy products, embodying the concept of "good medicine available in Hong Kong." Expanding the "1+" mechanism can attract more new drugs from around the world to register in Hong Kong, providing patients with more choices, strengthening the local drug regulatory capacity, promoting the development of relevant hardware and software, and talent, and further moving towards the "first-level approval." The government will innovate the system in conjunction with technological innovation to develop Hong Kong into an international medical innovation hub. According to the "Pharmacy and Poisons Ordinance".
Hong Kong stock abnormal | MegaEyes-B (06622) opens more than 9% higher, NVK002 nearsightedness treatment clinical trial shows positive results.
Megain Medical-B (06622) opened more than 9% higher, as of the publication, rose by 9.56%, at 1.49 Hong Kong dollars, with a turnover of 0.2213 million Hong Kong dollars.
Zhaoke Ophthalmology's Phase 3 Trial of Myopia Progression Drug Shows Positive Results
Zhaoke Ophthalmology-B(06622.HK): The positive top-line results of the two-year China Phase III clinical trial (CHINA CHAMP) of NVK002 for treating worsening myopia in children.
On October 23, Cholonhui announced that Zeoke Ophthalmology-B (06622.HK) released the topline results of the two-year Phase III clinical trial ("China CHAMP") of NVK002 (one of the company's core products). After two years of treatment, the study analysis showed that the NVK002 eye drop group (0.01% and 0.02% doses) had statistically significant differences in the main efficacy indicators compared to the placebo group, with the NVK002 eye drop group outperforming the placebo group and showing dose dependency. The safety of both doses of NVK002 is good, with patient compliance.
Express News | Zaokai Ophthalmology: The clinical trial of NVK2 for myopia treatment shows positive results.
Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space
Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.
Announcement Highlights | China Life Insurance issued 35 billion capital supplementary bonds; Zheng Zhigang resigned as the President of New World Development.
HSBC has completed the issuance of Hong Kong's first private digital bond, with a total amount of 1 billion Hong Kong dollars; junshi bio's JS125 has obtained a drug clinical trial approval letter.
Zhaoke Ophthalmology Completes Last Patient Visit for Trial of Macular Degeneration Drug
Chow's Ophthalmology-B (06622.HK): The final visit of the last patient in the TAB014 Phase III clinical trial was completed in China.
Glory9thdayTheMeanwhile,ZodiacEye-C(06622.HK)announced that TAB014(oneofthecompany'scorecandidateproperties)hascompletedthelastvisitforthelastpatientinPhaseIIIclinicaltrialfortreatingwet(neovascular)age-relatedmaculardegeneration('wAMD')onSeptember20,2024.Accordingtothedisclosure,TAB014PhaseIIIclinicaltrialisrandomized,double-blind,andnon-inferioritystudy.Theprimaryobjectiveofthestudyistoevaluate the best correction of the group receiving TAB014 treatment compared to the group receiving Lucentis treatment at week 52.
ZHAOKE OPHTH-B: 2024 Interim Report
Zhaoke Ophthalmology Glaucoma Eye Drops Get Marketing Approval; Shares Rise 3%
HK stocks surged, Shares of Mega Vision Group rose more than 5%, and the antiglaucoma drug Jingbeiqing was approved by the National Medical Products Administration for listing.
On September 20th, Chia Tai Ophthalmology-B (6622.HK) opened at a high of 5.19% and reported HK$1.42. In terms of news, the company announced that its research and development of the anti-glaucoma drug Beminitan prostaglandin eye drops (Cinzin) has been approved by the National Medical Products Administration for listing. The company stated that the Beminitan prostaglandin eye drops is the first single-dose Beminitan prostaglandin eye drops in China without preservatives, and is used to reduce intraocular pressure in patients with angle-closure glaucoma and ocular hypertension.
Express News | Zhaoke Ophthalmology, a Hong Kong Stock Exchange announcement, announced that Beimei Prostaglandin Eye Drops (Jingbeiqing) has been approved for marketing by the National Medical Products Administration (NMPA).
Research and development innovation, business cultivation, international perspective, examining the value growth logic of Chaoke Ophthalmology (6622.HK).
Over the next two years, Zhaoke Ophthalmology may usher in a period of intensive performance outbreaks.
Understanding the midterm performance of Meitu Eye Care (06622.HK) in 2024 in one picture.
On August 29, MediLink-Bev(06622.HK) announced its 2024 interim performance. Specific performance details will be explained below with a chart.
ZHAOKE OPHTH-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
MegaMedical-B (06622.HK) will hold a board of directors meeting on August 29 to approve the interim performance.
On August 16, Glorious Sun Ophthalmic (6622.HK) announced that the board of directors will hold a meeting on August 29, 2024 to approve the midterm performance of the company and its subsidiaries for the six months ending June 30, 2024 and to publish its announcement.
Zhaoke Ophthalmology Expects Losses to Shrink in H1
Megvii Ophthalmology-B (06622) issued a profit warning, expecting the mid-term loss to narrow by no more than 77 million yuan year on year.
Megain Medical Group-B (06622) has released an announcement stating that the board of directors expects the group to negotiate with the creditors and reach a debt restructuring agreement by June 30, 2024...
Analysis
Price Target
No Data
No Data